HCV treatment in patients with decompensated liver disease
Elizabeth C. Verna – 31 October 2017
Elizabeth C. Verna – 31 October 2017
Sarah R. Lieber, Michael W. Fried – 31 October 2017
John Ha, Robert J. Wong – 31 October 2017
Jean de Ville de Goyet, Bruce Morland, Piotr Czauderna – 31 October 2017
Elizabeth C. Verna – 31 October 2017
Puneet Puri, Suthat Liangpunsakul, Jeffrey E. Christensen, Vijay H. Shah, Patrick S. Kamath, Gregory J. Gores, Susan Walker, Megan Comerford, Barry Katz, Andrew Borst, Qigui Yu, Divya P. Kumar, Faridoddin Mirshahi, Svetlana Radaeva, Naga P. Chalasani, David W. Crabb, Arun J. Sanyal, for the TREAT Consortium – 30 October 2017 – Intestinal dysbiosis is implicated in alcoholic hepatitis (AH). However, changes in the circulating microbiome, its association with the presence and severity of AH, and its functional relevance in AH is unknown.
Gabriel Perlemuter – 30 October 2017
Jun Xu, Hsiao‐Yen Ma, Shuang Liang, Mengxi Sun, Gabriel Karin, Yukinori Koyama, Ronglin Hu, Oswald Quehenberger, Nicholas O. Davidson, Edward A. Dennis, Tatiana Kisseleva, David A. Brenner – 30 October 2017 – Cytochrome P450 2E1 (CYP2E1) plays an important role in alcohol and toxin metabolism by catalyzing the conversion of substrates into more polar metabolites and producing reactive oxygen species. Reactive oxygen species‐induced oxidative stress promotes hepatocyte injury and death, which in turn induces inflammation, activation of hepatic stellate cells, and liver fibrosis.
Jesús Quintero Bernabeu, Juan Ortega López, Javier Juampérez Goñi, Ecaterina Julio Tatis, Maria Mercadal‐Hally, Itxarone Bilbao Aguirre, Carlos Rodrigo Gonzalo de Liria, Ramon Charco Torra – 28 October 2017